Smithkline Beecham Corporation

Wyeth

Ponnal Nambi

Yuan Zhu

Ashok D Patil

Mark A Pullen

Jay Edward Wrobel

Michael David Collini

Ronald Charles Bernotas

Rayomand Jal Unwalla

Baihua Hu

John W Ullrich

Robert L Morris

Christopher P Miller

James Winfield Jetter

Robert R Singhaus, Jr

David H Kaufman

Elaine Quinet

Merle Elloso

Qiang-Yuan Liu

This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases.

Quinolines and pharmaceutical compositions thereof

This invention provides novel human LXR&#x3b1; variant polypeptides and nucleic acids encoding such polypeptides. This invention also provides the therapeutic, diagnostic, and research utilities as well as the production of such polynucleotides and polypeptides. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. 37 CFR 1.72(b).

Human LXR&#x3b1; variants

HOEFC11 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HOEFC11 polypeptides and polynucleotides in the design of protocols for the treatment of chronic renal failure, inflammatory diseases, myocardial ischemia, cancer, rheumatoid arthritis, cirrhotic liver disease, among others, and diagnostic assays for such conditions.

HAS2 splicing variant HOEFC11: a target in chronic renal failure, inflammatory diseases and myocardial ischemia

HAS2 splicing variant HOEFC11: a target in chronic renal failure,

The present invention relates to treatment of conditions wherein protein Kinase C inhibition is indicated.

Protein Kinase C inhibitor

Medicament

Growing community of inventors

Berwyn, PA, United States of America

Ponnal Nambi